Related Experiment Videos
The predictive value of C-reactive protein in end-stage renal disease: is it clinically significant?
Frank M van der Sande1, Jeroen P Kooman, Karel M L Leunissen
1Division of Internal Medicine and Nephrology, University Hospital Maastricht, Maastricht, The Netherlands. fvs@groupwise.azm.nl
Insights
C-reactive protein (CRP) is linked to cardiovascular disease in dialysis patients, but its predictive value is uncertain when other risk factors are considered. Statins may lower CRP but not cardiovascular mortality in diabetic dialysis patients.
Area of Science:
- Nephrology
- Cardiology
- Clinical Chemistry
Background:
- Cardiovascular disease (CVD) is the primary cause of mortality in end-stage renal disease (ESRD) patients.
- Mineral and bone metabolism disturbances and inflammation contribute to heightened CVD risk in ESRD.
- C-reactive protein (CRP) is a marker of inflammation with a known association with atherosclerosis.
Purpose of the Study:
- To evaluate the clinical evidence and predictive value of C-reactive protein (CRP) for cardiovascular events in ESRD patients.
- To investigate the role of CRP as a marker, causative agent, or consequence of atherosclerotic vascular disease in dialysis patients.
Main Methods:
- Review of existing studies examining the association between CRP and cardiovascular disease in the general and ESRD populations.
- Analysis of the impact of adjusting for traditional risk factors on the predictive power of CRP.
- Examination of CRP level variability and the effects of interventions like statins in dialysis patients.
Main Results:
- A statistical association exists between CRP and CVD, but its predictive power diminishes significantly when adjusted for other risk factors.
- The precise role of CRP in atherosclerotic vascular disease remains unclear in both general and dialysis populations.
- CRP levels in dialysis patients are highly variable and influenced by concurrent health issues.
- Statins can reduce CRP levels in dialysis patients, but do not decrease cardiovascular mortality in diabetic patients undergoing dialysis.
Conclusions:
- The clinical utility of CRP as an independent predictor of cardiovascular events in ESRD patients is questionable.
- Further research is needed to clarify the complex relationship between CRP, inflammation, and atherosclerosis in ESRD.
- Interventions targeting CRP may not translate to reduced cardiovascular mortality in all ESRD subpopulations, particularly diabetic patients.
Abstract:
Cardiovascular disease is the leading cause of death in patients with end-stage renal disease. Besides traditional risk factors, disturbances in mineral and bone metabolism and inflammation are thought to be responsible for the increased risk of death. In the last years C-reactive protein (CRP) has gained a lot of attention in the general population, especially with regard to its link with atherosclerosis. Although several studies suggest that CRP may be useful as a parameter in predicting future cardiovascular events in both the general population and in patients with end-stage renal disease, there is doubt about the clinical evidence of this assumption. A statistical association between CRP and cardiovascular disease was observed in various studies, but the predictive power of this association is markedly diminished when adjusted for other risk factors. The relative contributions of CRP as a marker, as a causative agent, or as a consequence of atherosclerotic vascular disease are unclear, both in the general population and in the dialysis population. The CRP levels are highly variable and influenced by intercurrent events in dialysis patients. In dialysis patients, it is possible to reduce the CRP levels by statins, although these agents do not reduce the cardiovascular mortality in diabetic dialysis patients.
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury I: Introduction
Serum Studies: Renal Function Tests